However, its capacity to induce pro-inflammatory transcription factors, such as NF-kB, and modulate pathways including MAPK, PI3K, and ROS (187), suggests that Visfatin might act as a potential tumor-promoting factor in lung cancer bone metastasis through upregulation of MMP-2, enhanced differentiation of OBs, and the promotion of inflammatory responses in MSCs, thereby indirectly facilitating osteolysis and the progression of pulmonary cancer bone metastasis. This evidence concerns the gene NAMPT and neoplasm.